Bavarian Nordics mpox- og koppevaccine opnår godkendelse i Schweiz
March 13, 2024 08:29 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 13. marts 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at lægemiddelmyndighederne i Schweiz, Swissmedic, har godkendt JYNNEOS® (MVA-BN) til aktiv immunisering mod sygdom...
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland
March 13, 2024 08:29 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS® (MVA-BN) for active immunization...
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
March 12, 2024 12:30 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 12. marts 2024 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
March 12, 2024 12:30 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, March 12, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding...
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
March 06, 2024 01:50 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 6. marts 2024 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
March 06, 2024 01:50 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, March 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding...
Bavarian Nordic offentliggør årsrapport for 2023
March 06, 2024 01:38 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 6. marts 2024 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag årsrapporten for 2023. De konsoliderede og reviderede finansielle resultater var i overensstemmelse med de...
Bavarian Nordic Publishes Annual Report 2023
March 06, 2024 01:38 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, March 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2023. The consolidated, audited results were in line with the preliminary results, announced...
Bavarian Nordics vaccinekandidat mod chikungunya er blevet tildelt fremskyndet vurdering af Det Europæiske Lægemiddelagentur
February 23, 2024 01:35 ET
|
Bavarian Nordic A/S
Fremskyndet vurdering muliggør en kortere behandlingstid for godkendelsesansøgningen hos EMA.Bavarian Nordic forventer at indsende ansøgning om markedsføringstilladelse for CHIKV VLP til EMA i...
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency
February 23, 2024 01:35 ET
|
Bavarian Nordic A/S
Accelerated assessment allows for a shorter review period with EMA.Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024. ...